Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Health
Pharmalot
STAT+
The Readout

Rough times for med tech startups & a VC fund plays it safe

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Oct. 18, 2016

Reprints
The READOUT
Alex Hogan/STAT

The Readout for October 18, 2016

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Biogen board and C-suite are in step as they…
Biogen board and C-suite are in step as they eye M&A opportunities, new CEO says
Academia’s postdoc system is teetering, imperiling efforts to diversify…
Academia’s postdoc system is teetering, imperiling efforts to diversify life sciences
Tired of ‘dead end’ approach, herpes patients mobilize to…
Tired of ‘dead end’ approach, herpes patients mobilize to demand government action
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories